News | December 26, 2024
Kwality Pharmaceuticals receives approval for Tamoxifen 20mg Tablet in South Africa
This approval is a significant achievement in expanding the availability of this critical therapeutic,
This approval is a significant achievement in expanding the availability of this critical therapeutic,
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
Merck has also decided to end the favezelimab clinical development program
Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines
IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy
First and only PARP inhibitor to improve overall survival in early breast cancer
Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate
Showing High Overall Response Rate (ORR) with durable responses and favorable safety profile in patients with heavily pretreated multiple myeloma
CLL is one of the most common leukemias among adults affecting more than 200,000 people in the US
Based on data, 1.75 mg/kg dose established as recommended dose for Phase 3 trial of this investigational antibody-drug conjugate
Subscribe To Our Newsletter & Stay Updated
